

## Product Data Sheet

## Fsh receptor-binding inhibitor fragment(bi-10)

Cat. No.:	HY-P4190	
CAS No.:	163973-98-6	
Molecular Formula:	C <sub>42</sub> H <sub>67</sub> N <sub>13</sub> O <sub>19</sub>	
Molecular Weight:	1058.06	
Sequence:	Thr-Glu-Asn-Leu-Glu-Pro-Asn-Gly-Glu-Gly-NH2	
Sequence Shortening:	TENLEPNGEG-NH2	
Target:	GnRH Receptor	
Pathway:	GPCR/G Protein	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY			
Description	FSH receptor-binding inhibitor fragment(bi-10) is a potent FSH antagonist. FSH receptor-binding inhibitor fragment(bi-10) blocks the binding of FSH to FSHR, and alteres FSH action at the receptor level. FSH receptor-binding inhibitor fragment(bi-10) results in the suppression of ovulation and causes follicular atresia of mice. FSH receptor-binding inhibitor fragment(bi-10) has the potential for utilizing to restrain the carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and ERβ in the ovaries <sup>[1]</sup> .		
In Vivo	FSH receptor-binding inhibitor fragment(bi-10) (10, 20, 30, 40 mg/kg; Intramuscularly injection; once a day for five consecutive days) with high dose (30 mg/kg to 40 mg/kg) can suppress ovarian and follicular development, and attenuate expression levels of ERβ and FSHR mRNAs and proteins in the ovaries, additionally inhibit E2 production <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Prepuberty Kunming female mice of 21-days old and body weight of 22.3 $\pm 1.52 g^{[1]}$	
	Dosage:	10, 20, 30, 40 mg/kg	
	Administration:	Intramuscularly injection; once a day for five consecutive days	
	Result:	Could attenuate FSH promoting effect on the follicular development, resulting in the poor maturation of ovarian follicles. High dose (40mg/kg) treatment blocked the follicle development of mice. High dose of FRBI (40mg/kg) treatment blocked the follicle development of mice.	

## REFERENCES

[1]. Gong Zhuandi, et al. FSH receptor binding inhibitor restrains follicular development and possibly attenuates carcinogenesis of ovarian cancer through down-regulating expression levels of FSHR and ER $\beta$  in normal ovarian tissues. Gene. 2018 Aug 20;668:174-181.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA